Literature DB >> 9676649

A novel orally active endothelin-A receptor antagonist, ZD1611, prevents chronic hypoxia-induced pulmonary hypertension in the rat.

R A Bialecki1, C Stinson-Fisher, W Murdoch, D Bertelsen, M Desiato, W Rumsey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9676649     DOI： 10.1378/chest.114.1_supplement.91s

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  3 in total

1.  Mechanisms of NFATc3 activation by increased superoxide and reduced hydrogen peroxide in pulmonary arterial smooth muscle.

Authors:  Juan Manuel Ramiro-Diaz; Wieslawa Giermakowska; John M Weaver; Nikki L Jernigan; Laura V Gonzalez Bosc
Journal:  Am J Physiol Cell Physiol       Date:  2014-08-27       Impact factor: 4.249

2.  Endothelin type A receptor antagonist normalizes blood pressure in rats exposed to eucapnic intermittent hypoxia.

Authors:  Kyan J Allahdadi; Tom W Cherng; Hemanth Pai; Ana Q Silva; Benjimen R Walker; Leif D Nelin; Nancy L Kanagy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-30       Impact factor: 4.733

3.  Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension.

Authors:  Djuro Kosanovic; Baktybek Kojonazarov; Himal Luitel; Bhola K Dahal; Akylbek Sydykov; Teodora Cornitescu; Wiebke Janssen; Ralf P Brandes; Neil Davie; Hossein A Ghofrani; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Ralph T Schermuly
Journal:  Respir Res       Date:  2011-06-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.